- Home
- FORR vs CATX Comparison
FORR vs CATX Comparison
Compare FORR & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | CATX |
|---|---|---|
| Founded | 1983 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.1M | 162.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | FORR | CATX |
|---|---|---|
| Price | $6.63 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 106.5K | ★ 2.0M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,871,000.00 | $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.61 | $1.60 |
| 52 Week High | $17.51 | $5.39 |
Technical Indicators
Market Signals| Indicator | FORR | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 48.74 |
| Support Level | $6.94 | $2.07 |
| Resistance Level | $7.50 | $2.39 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 3.57 | 75.13 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.